Valeant To Use Bausch Buy To Expand In China, Other Emergings
This article was originally published in PharmAsia News
Executive Summary
Valeant Pharmaceuticals International plans to use its $8.7 billion acquisition of Bausch & Lomb Holdings to expand its own presence in China and other emerging markets, primarily for its ophthalmology products.